Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
1.500
+0.030 (2.04%)
At close: Oct 24, 2025, 4:00 PM EDT
1.480
-0.020 (-1.33%)
After-hours: Oct 24, 2025, 7:50 PM EDT
Alector Revenue
Alector had revenue of $7.87M in the quarter ending June 30, 2025, a decrease of -47.80%. This brings the company's revenue in the last twelve months to $81.13M, up 46.78% year-over-year. In the year 2024, Alector had annual revenue of $100.56M with 3.60% growth.
Revenue (ttm)
$81.13M
Revenue Growth
+46.78%
P/S Ratio
1.83
Revenue / Employee
$340,882
Employees
238
Market Cap
151.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100.56M | 3.50M | 3.60% |
| Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
| Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
| Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
| Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ALEC News
- 2 days ago - Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce - Benzinga
- 3 days ago - Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic - GlobeNewsWire
- 3 days ago - Alector shares plunge after dementia drug fails to slow disease progression - Reuters
- 3 days ago - Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update - GlobeNewsWire
- 14 days ago - 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
- 4 weeks ago - Alector, Inc. - Special Call - Seeking Alpha
- 5 weeks ago - Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs - GlobeNewsWire
- 6 weeks ago - Alector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha